Barrier function and microbiotic dysbiosis in atopic dermatitis

Clinical, Cosmetic and Investigational Dermatology

Volumn 8, Issue , 2015, Pages 479-483

  Seite, Sophie ^a   Bieber, Thomas ^b  

^a La Roche Posay Pharmaceutical Laboratories   (France)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Atopic dermatitis; Dermocosmetic; Eczema; Immunity; Microbiome; Skin barrier

Indexed keywords

2 HYDROXYACID; ALCOHOL DERIVATIVE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CARBOMER; CERAMIDE; COSMETIC; EMOLLIENT AGENT; ESTER; FATTY ACID; GLYCEROL; HUMECTANT; HYALURONIC ACID; LACTIC ACID; LIQUID PARAFFIN; PETROLATUM; PROBIOTIC AGENT; TRIACYLGLYCEROL; UREA; VEGETABLE OIL;

ARTICLE; ATOPIC DERMATITIS; DISEASE EXACERBATION; DYSBIOSIS; HUMAN; NONHUMAN; PERSONAL HYGIENE; REMISSION; SKIN FLORA; SKIN PERMEABILITY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; VITREOSCILLA; XANTHOMONADACEAE;

EID: 84941923359     PISSN: None     EISSN: 11787015     Source Type: Journal    
DOI: 10.2147/CCID.S91521     Document Type: Article

References (40)

1. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–1494.
2. Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ. Atopic dermatitis and the atopic march revisited. Allergy. 2013;69:17–27.
3. Ring J, Alomar A, Bieber T, etal. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012; 26(8):1045–1060.
4. Eichenfield LF, Tom WL, Chamlin SL, etal. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–351.
5. Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013;68(8):974–982.
6. Smith FJ, Irvine AD, Terron-Kwiatkowski A, etal. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet. 2006;38(3):337–342.
7. Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233–246.
8. Kuo IH, Yoshida T, De Benedetto A, Beck LA. The cutaneous innate immune response in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131(2):266–278.
9. Kong HH, Oh J, Deming C, etal. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850–859.
10. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011;164(2):415–428.
11. Ring J, Alomar A, Bieber T, etal. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012; 26(9):1176–1193.
12. Simon D, Bieber T. Systemic therapy for atopic dermatitis. Allergy. 2014;69(1):46–55.
13. Bieber T, Straeter B. Off-label prescriptions for atopic dermatitis in Europe. Allergy. 2015;70(1):6–11.
14. Howell MD, Parker ML, Mustelin T, Ranade K. Past, present, and future for biologic intervention in atopic dermatitis. Allergy. 2015; 70(8):887–896.
15. Lane ME, Hadgraft J, Oliveira G, Vieira R, Mohammed D, Hirata K. Rational formulation design. Int J Cosmet Sci. 2012;34(6):496–501.
16. Hon KL, Ching GK, Leung TF, Choi CY, Lee KK, Ng PC. Estimating emollient usage in patients with eczema. Clin Exp Dermatol. 2010; 35(1):22–26.
17. Dreno B, Araviiskaia E, Berardesca E, etal. The science of dermocosmetics and its role in dermatology. J Eur Acad Dermatol Venereol. 2014;28(11):1409–1417.
18. Grice EA, Kong HH, Conlan S, etal. Topographical and temporal diversity of the human skin microbiome. Science. 2009;324(5931):1190–1192.
19. Grice EA, Segre JA. The human microbiome: our second genome. Annu Rev Genomics Hum Genet. 2012;13:151–170.
20. Ong PY, Ohtake T, Brandt C, etal. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347(15): 1151–1160.
21. Nakatsuji T, Gallo RL. Antimicrobial peptides: old molecules with new ideas. J Invest Dermatol. 2012;132(3 pt 2):887–895.
22. Grice EA. The skin microbiome: potential for novel diagnostic and therapeutic approaches to cutaneous disease. Semin Cutan Med Surg. 2014;33(2):98–103.
23. Seite S, Flores GE, Henley JB, etal. Microbiome of affected and unaffected skin of patients with atopic dermatitis before and after emollient treatment. J Drugs Dermatol. 2014;13(11):1365–1372.
24. Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol. 2011; 9(4):244–253.
25. Yamamura S, Morita Y, Hasan Q, Yokoyama K, Tamiya E. Keratin degradation: a cooperative action of two enzymes from Stenotrophomonas sp. Biochem Biophys Res Commun. 2002;294(5):1138–1143. [Erratum in: Biochem Biophys Res Commun. 2002;295(4):1034].
26. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009;123(5):e808–e814.
27. Panduru M, Panduru NM, Salavastru CM, Tiplica GS. Probiotics and primary prevention of atopic dermatitis: a meta-analysis of randomized controlled studies. J Eur Acad Dermatol Venereol. 2015;29(2): 232–242.
28. Muraro A, Halken S, Arshad SH, etal. EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy. Allergy. 2014;69(5):590–601.
29. Kim SO, Ah YM, Yu YM, Choi KH, Shin WG, Lee JY. Effects of probiotics for the treatment of atopic dermatitis: a meta-analysis of randomized controlled trials. Ann Allergy Asthma Immunol. 2014;113(2): 217–226.
30. Wang IJ, Wang JY. Children with atopic dermatitis show clinical improvement after Lactobacillus exposure. Clin Exp Allergy. 2015; 45(4):779–787.
31. Drago L, De Vecchi E, Toscano M, Vassena C, Altomare G, Pigatto P. Treatment of atopic dermatitis eczema with a high concentration of Lactobacillus salivarius LS01 associated with an innovative gelling complex: a pilot study on adults. J Clin Gastroenterol. 2014;48(Suppl 1):S47–S51.
32. Niccoli AA, Artesi AL, Candio F, etal. Preliminary results on clinical effects of probiotic Lactobacillus salivarius LS01 in children affected by atopic dermatitis. J Clin Gastroenterol. 2014;48(Suppl 1):S34–S36.
33. Gueniche A, Knaudt B, Schuck E, etal. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol. 2008;159(6):1357–1363.
34. Volz T, Skabytska Y, Guenova E, etal. Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells. J Invest Dermatol. 2014;134(1): 96–104.
35. Mahe YF, Perez MJ, Tacheau C, etal. A new Vitreoscilla filiformis extract grown on spa water-enriched medium activates endogenous cutaneous antioxidant and antimicrobial defenses through a potential Toll-like receptor 2/protein kinase C, zeta transduction pathway. Clin Cosmet Investig Dermatol. 2013;6:191–196.
36. Seité S, Zelenkova H, Martin R, Fierer N. Using a Specific Emollient to Manage Skin Microbiome Dysbiosis. Vancouver, Canada: World Congress of Dermatology; 2015.
37. Biedermann T, Skabytska Y, Kaesler S, Volz T. Regulation of T cell immunity in atopic dermatitis by microbes: the Yin and Yang of cutaneous inflammation. Front Immunol. 2015;6:353.
38. Flohr C, Mann J. New approaches to the prevention of childhood atopic dermatitis. Allergy. 2014;69(1):56–61.
39. Simpson EL, Chalmers JR, Hanifin JM, etal. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818–823.
40. Fukuie T, Nomura I, Horimukai K, etal. Proactive treatment appears to decrease serum immunoglobulin-E levels in patients with severe atopic dermatitis. Br J Dermatol. 2010;163(5):1127–1129.